ReviewBritish journal of pharmacology2005
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.
Review in British journal of pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of distal transradial access for coronary angiography and percutaneous coronary intervention: a meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.International journal of molecular sciences · 2020Review
- The evolution of anticoagulant therapy.Blood transfusion = Trasfusione del sangue · 2016Review
- Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Arthroplasty: Changing Trends.Current reviews in musculoskeletal medicine · 2014Article
- Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2009Article
- M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice.Journal of thrombosis and thrombolysis · 2009Article
- Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.The journal of spinal cord medicine · 2008Article
- Development of oral anticoagulants.British journal of clinical pharmacology · 2007Article
- Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery.Drugs · 2006Review
- New treatment options for stroke prevention in atrial fibrillation.Current treatment options in cardiovascular medicine · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.